Cannabis Sativa (CBDS) 10-Q 8 Dec 15 2015 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Oct. 14, 2015
Document and Entity Information:
Entity Registrant Name	Cannabis Sativa, Inc.
Document Type	10-Q
Document Period End Date	Sep. 30, 2015
Amendment Flag	false
Entity Central Index Key	1,360,442
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		16,149,738
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3
Trading Symbol	cbds

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Current Assets
Cash and Cash Equivalents	$ 21,885	$ 25,994
Accounts Receivable, Net	5,818
Employee Advance	44	13
Inventories	17,336	17,837
Available-for-Sale Securities	4,876	4,876
Prepaids	1,757,838	625,000
Total Current Assets	1,807,797	673,720
Property and Equipment, Net	6,103	7,037
Intangible Assets	2,918,095	2,999,292
Deposits	4,236	1,031
Total Assets	4,736,231	3,681,080
Current Liabilities:
Accounts Payable and Accrued Expenses	268,208	482,942
Due to Related Parties - Short Term		2,472,086
Accrued Interest		5,667
Total Current Liabilities	268,208	2,960,695
Due to Related Parties - Long Term		1,000,000
Total Liabilities	268,208	3,960,695
Stockholders' Equity (Deficit):
Preferred stock $0.001 par value; 5,000,000 shares authorized; 1,928,585 and -0- issued and outstanding, respectively	1,929
Common stock $0.001 par value; 45,000,000 shares authorized; 16,097,238 and 15,114,738 shares issued and outstanding, respectively	16,098	15,115
Additional Paid-In Capital	56,914,038	46,614,604
Accumulated Other Comprehensive Income	4,876	4,876
Accumulated Deficit	(52,469,812)	(46,915,104)
Total Cannabis Sativa, Inc. Stockholders' Equity (Deficit)	4,467,129	(280,509)
Non-Controlling Interest	894	894
Total Stockholders' Equity (Deficit)	4,468,023	(279,615)
Total Liabilities and Stockholders' Equity (Deficit)	$ 4,736,231	$ 3,681,080

CONDENSED CONSOLIDATED BALANCE3

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - $ / shares	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position
Common Stock, par or stated value	$ 0.001	$ 0.001
Common Stock, shares authorized	45,000,000	45,000,000
Common Stock, shares issued	16,097,238	15,114,738
Common Stock, shares outstanding	16,097,238	15,114,738
Preferred Stock, par or stated value	$ 0.001	$ 0.001
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, shares issued	1,928,585	0
Preferred Stock, shares outstanding	1,928,585	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement
Revenues	$ 6,378	$ 1,114	$ 8,096	$ 2,786
Cost of Revenues	13,172	387	14,575	2,018
Gross Profit (Loss)	(6,794)	727	(6,479)	768
General and Administrative Expenses	1,762,707	171,132	5,413,153	336,293
Loss from Operations	(1,769,501)	(170,405)	(5,419,632)	(335,525)
Other Expenses
Interest Expense	(9,571)	(5,635)	(26,635)	(18,731)
Realized Loss on Available For Sale Securities		(40,000)		(40,000)
Total Other Expenses	(9,571)	(45,635)	(26,635)	(58,731)
Loss Before Income Taxes	$ (1,779,072)	$ (216,040)	$ (5,446,267)	$ (394,256)
Income Taxes
Loss from Continuing Operations	$ (1,779,072)	$ (216,040)	$ (5,446,267)	$ (394,256)
Loss from Discontinued Operations	(244)		(108,439)
Net Loss For the Period	$ (1,779,316)	$ (216,040)	$ (5,554,706)	$ (394,256)
Income (Loss) Attributable to Non-Controlling Interest
Net Loss Attributable To Cannabis Sativa, Inc.	$ (1,779,316)	$ (216,040)	$ (5,554,706)	$ (394,256)
Net Loss per Common Share:
Basic & Diluted Continuing Operations	$ (0.11)	$ (0.01)	$ (0.35)	$ (0.03)
Basic & Diluted Discontinued Operations	$ 0	$ 0	$ (0.01)	$ 0
Weighted Average Common Shares Outstanding:
Basic & Diluted	16,074,412	15,014,738	15,925,242	11,700,568

CONDENSED CONSOLIDATED STATEME5

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss for the Period	$ (5,554,706)	$ (394,256)
Adjustments to Reconcile Net Loss for the Period to Net Cash Used in Operating Activities:
Depreciation and Amortization	90,053	40,457
Stock Issued for Services	3,215,655
Contributed Capital	16,426	38,549
Amortization of Prepaid	1,813,041
Amortization of Note Discount		5,559
Imputed Interest on Loans	9,316
Realized Loss on Available for Sale Securities		40,000
Changes in assets and liabilities:
Accounts Receivable	(5,818)
Inventories	501	(16,117)
Prepaids	(2,485)	1,784
Employeee Advances	(31)
Deposits	(3,205)	(150)
Accounts Payable and Accrued Expenses	141,164	53,878
Intercompany Accounts, Net Payable		(5,315)
Accrued Interest	1,655	1,348
Net Cash Used in Operating Activities:	(278,434)	(234,263)
Net Cash Provided by Discontinued Operating Activities:	6,840
Cash Flows from Investing Activities:
Purchase of Fixed Assets and Intangibles	(8,410)	(21,625)
Proceeds from Sale of Available for Sale Securities		100,000
Cash Acquired in Merger		27,707
Net Cash Provided (Used) in Investing Activities:	$ (8,410)	$ 106,082
Net Cash Provided by Discontinued Investing Activities:
Cash Flows from Financing Activities:
Proceeds from Related Parties	$ 316,240	$ 223,296
Payments to Related Parties	(40,345)	(69,093)
Net Cash Provided by Financing Activities:	$ 275,895	$ 154,203
Net Cash Provided by Discontinued Financing Activities:
NET DECREASE IN CASH AND CASH EQUIVALENTS	$ (4,109)	$ 26,022
Cash and Cash Equivalents - Beginning of Period	25,994	14,863
Cash and Cash Equivalents - End of Period	$ 21,885	$ 40,885
Supplemental Disclosure of Cash Flow Activities:
Interest
Income taxes
Supplemental Disclosures of Non Cash Activities:
Conversion of debt to equity		$ 78,112
Acquisition of assets in merger		$ 3,198,258
Shares issued for accrued liabilities	$ 362,250
Shares issued for prepaid items	3,246,925
Preferred shares issued for related party payables	$ 3,747,668

1. Summary of Significant Accou

1. Summary of Significant Accounting Policies and Use of Estimates	9 Months Ended
	Sep. 30, 2015
Notes
1. Summary of Significant Accounting Policies and Use of Estimates:	1. Summary of Significant Accounting Policies and Use of Estimates: Presentation of Interim Information: The condensed consolidated financial statements included herein have been prepared by Cannabis Sativa, Inc., formerly named Ultra Sun Corp. (“we”, “us”, “our” or “Company”), without audit, pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) and should be read in conjunction with the annual report on Form 10-k filed with the SEC April 15, 2015. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted, as permitted by the SEC, although we believe the disclosures, which are made, are adequate to make the information presented not misleading. Further, the condensed financial statements reflect, in the opinion of management, all normal recurring adjustments necessary to present fairly our financial position at September 30, 2015, and the results of our operations and cash flows for the periods presented. Interim results are subject to significant seasonal variations and the results of operations for the period ended September 30, 2015 are not necessarily indicative of the results to be expected for the full year. Nature of Corporation: We were incorporated under the laws of Nevada in November 2004 as Ultra Sun Corp. On November 13, 2013, we changed our name to Cannabis Sativa, Inc. Our wholly-owned subsidiary Kush was acquired by us in June 2014 in exchange for shares of our common stock. Our wholly-owned subsidiary Wild Earth Naturals, Inc. (“Wild Earth”) was acquired by us in July 2013 in exchange for shares of our common stock. The acquisition of Kush resulted in a change of control of the Company and at or after the closing of the acquisition of Kush, the persons designated by Kush became the officers and directors of the Company. From our inception through September 30, 2013 we were engaged in the tanning salon business and operated a tanning salon in Saratoga Springs, Utah under the name “Sahara Sun Tanning.” As a result of our acquisition of Wild Earth in July 2013, we became engaged in the herbal skin care products business. On September 30, 2013 we sold the assets of the tanning salon business to a third party. As a result of our acquisition of Kush in June 2014, along with our Wild Earth operations we are now engaged in the developing and promoting of natural cannabis products. The following unaudited proforma condensed combined statement of operations reflects the results of operations of CANNABIS SATIVA for the nine months ended September 30, 2014, the results of operations for WILD EARTH NATURALS for the nine months ended September 30, 2014, and the results of operations for KUSH for the nine months ended September 30, 2014 as if the Companies had been consolidated effective January 1, 2014. Cannabis Sativa Wild Earth Naturals Kush Proforma Revenue $- $2,786 $- $2,786 Cost of revenue - 2,018 - 2,018 Gross profit - 768 - 768 General and adminstrative expense 5,699 262,964 278,374 547,037 Other expense Realized loss from for sale securities - 377,440 377,440 Interest expense 6,908 11,823 - 18,731 Loss from continued operations (12,607) (274,019) (655,814) (942,440) Net loss $(12,607 $(274,019 $(655,814 $(942,440 Development Stage Activities and Operations: Wild Earth has been in its initial stages of formation and for the nine months ended September 30, 2015 had minimal revenues. A development stage activity is one in which all efforts are devoted substantially to establishing a new business and even if planned principal operations have commenced, revenues are insignificant. Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Accounts Receivable: We estimate credit loss reserves for accounts receivable on an individual receivable basis. A specific impairment allowance reserve is established based on expected future cash flows and the financial condition of the debtor. We charge off customer balances in part or in full when it is more likely than not that we will not collect that amount of the balance due. We consider any balance unpaid after the contract payment period to be past due. At September 30, 2015 the company has established an allowance for doubtful accounts of $3,697. Inventory: The Company calculates inventory using the average cost method to value inventory. Inventory cost includes those costs directly attributable to the product before sale. Fair Value of Financial Instruments: The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable, accrued liabilities, and notes payable approximate fair value given their short term nature or effective interest rates. Cash and Cash Equivalents: For financial accounting purposes, cash and cash equivalents are considered to be all highly liquid investments purchased with an initial maturity of three (3) months or less. Earnings per Share: Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the period and contains no dilutive securities. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. As of September 30, 2015 and 2014, the Company has no outstanding potentially dilutive securities. Revenue Recognition: The Company recognizes revenue from product sales or services rendered when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable, and collectability is reasonably assured. Intangible Assets: Intangible assets are comprised of patents, trademarks, the Company’s “CBDS.com” website domain and intellectual property rights. The patent is being amortized using the straight-line method over its economic life, which is estimated to be twenty (20) years. The trademark, which is still in the application phase, is expected to have an indefinite useful life. The CBDS.com website is expected to have an indefinite useful life. The intellectual property rights are being amortized using the straight-line month over its economic life, which is estimated to be (20) years. Income Taxes: The Company estimates the annual tax rate based on projected taxable income for the full year and records a quarterly income tax provision in accordance with the anticipated annual rate. As the year progresses, we refine the estimates of the year’s taxable income as new information becomes available, including year-to-date financial results. This continual estimation process can result in a change to the expected effective tax rate for the year. When this occurs, the Company adjusts the income tax provision during the quarter in which the change in estimate occurs so that the year-to-date provision reflects the expected annual tax rate. Significant judgment may be required in determining the Company’s effective tax rate and in evaluating our tax positions. The effective income tax rate of 0% for the periods ended September 30, 2015 and 2014 differed from the statutory rate, due primarily to net operating losses incurred by the Company in the respective periods. For the nine months ended September 30, 2015 a tax benefit of approximately $664,000 would have been generated. For the nine months ended September 30, 2014 a tax benefit of approximately $134,000 would have been generated. However, all benefits have been fully offset through an allowance account due to the uncertainty of the utilization of the net operating losses. As of September 30, 2015 the Company had net operating losses of approximately $17,925,000resulting in a deferred tax asset of approximately $664,000. As of September 30, 2014 the Company had net operating losses of approximately $336,000 resulting in a deferred tax asset of approximately $134,000. The Company has established a valuation allowance in the full amount of the deferred tax asset due to the uncertainty of the utilization of operating losses in future periods. Pending Accounting Pronouncements: There have been no recent accounting pronouncements issued which are expected to have a material effect on the Company’s financial statements.

2. Eden Holdings Llc

2. Eden Holdings Llc	9 Months Ended
	Sep. 30, 2015
Notes
2. Eden Holdings Llc	2. Eden Holdings LLC During the quarter ended September 30, 2014, the Company created Eden Holdings LLC. The purpose of the entity is to hold the intellectual property of Cannabis Sativa, Inc. As of September 30, 2015 there has been no activity in the LLC.

3. Available-for-sale Securitie

3. Available-for-sale Securities	9 Months Ended
	Sep. 30, 2015
Notes
3. Available-for-sale Securities	3. Available-for-Sale Securities On January 10, 2014 the Company received 10,835 shares of BioAdaptives, Inc. as a result of Kush’s holdings in Hemp, Inc. The shares were received when Hemp, Inc. completed a spin-off of BioAdaptives, Inc. Each 923 shares of Hemp, Inc. received 1 share of BioAdaptives, Inc. At the time of the spin-off, Kush, Inc. was the owner of 10,000,000 shares of Hemp, Inc. common stock. This resulted in Kush receiving 10,835 shares of BioAdaptives, Inc. At September 30, 2015 the market price of BioAdaptives, Inc. was $.45 per share resulting in a value of $4,876. Available-for-sale securities are an investment in a marketable trading security. As such it will be adjusted to fair market value at each reporting date. The unrealized price variation will be reflected on our statement of comprehensive income (loss) as well as in our equity section of our balance sheet as an accumulated comprehensive loss. The following is a summary of the Company’s available-for-sale securities at September 30, 2015: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (Net Carrying Amount) Accumulated Other Comprehensive Income Equity Securities $- $4,876 $- $4,876 $4,876 Total Available-for-Sale Securities $- $4,876 $- $4,876 $4,876

4. Fair Value Measurements

4. Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Notes
4. Fair Value Measurements	4. Fair Value Measurements We adopted ASC Topic 820 for financial instruments measured at fair value on a recurring basis. ASC Topic 820 defines fair value, establishes a framework for measuring fair value in accordance with accounting principles generally accepted in the United States and expands disclosures about fair value measurements. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. ASC Topic 820 establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). These tiers include: · Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; · Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and · Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts receivable, inventory, notes payable, accounts payable, accrued liabilities approximate fair value given their short term nature or effective interest rates. We measure certain financial instruments at fair value on a recurring basis. As of September 30, 2015, assets and liabilities measured at fair value on a recurring basis were as follows: Total Level 1 Level 2 Level 3 Assets: Available-for-sale securities $4,876 $4,876 $- $- Total assets measured at fair value $4,876 $4,876 $- $- Liabilities: $- $- $- $- Total liabilities measured at fair value $- $- $- $-

5. Due To Related Parties

5. Due To Related Parties	9 Months Ended
	Sep. 30, 2015
Notes
5. Due To Related Parties	5. Due to Related Parties During the nine months ended September 30, 2015 the Company received additional short-term advances from related parties and officers of the Company to cover operating expenses in the amount of $58,500. As of September 30, 2015, all net advances to the Company were $-0-, as all debt was paid through issuance of preferred stock. These advances were non-interest bearing in nature. The Company has imputed interest on these sums at the rate of 5% per annum and has recorded interest expense related to these balances in the amount of $25,742. Because the related parties do not expect the imputed interest to be repaid, the interest has been recorded as a contribution of capital at September 30, 2015. Kush, a wholly-owned subsidiary of the Company, is a party to three individual license agreements with Steve Kubby. Pursuant to the license agreements Kush owed a total of $3,060,000 in license fees to Mr. Kubby at various dates. On June 30, 2015 Kush sold $3,060,000 of its originally price Intellectual Property to CBDS, net of $165,750 of accumulated amortization for a gross sales price of $2,894,250 for which CBDS assumed a liability to Steve Kubby, the licensor of the intellectual property, of $2,890,499. Additionally, CBDS received Kush’s interest in K-Pal, which is the holder of the intellectual property in the amount of $8,938, less a non-controlling interest of $894. Correspondingly, for Cannabis Sativa's books as of June 30, 2015, the Long Term Investment in K-Pal was booked at $8,938 and the non-controlling interest of $894 was recognized as a reduction of equity. The acquisition of intellectual property assets was also booked for $3,060,000 which had accumulated amortization of $165,750 and based on agreement with Steve Kubby, all liability to him was retired in exchange for 1,500,000 shares of Cannabis Sativa Preferred Stock at par value of $.001, resulting in a credit to the Preferred Stock account of $1,500, with the balance to Paid in Capital of $2,888,999. On September 30, 2015, an agreement was entered into by the Company to exchange $857,170 in debt held by three related parties for 428,585 shares of the Company's preferred stock based on the common share closing price on September 29, 2015 of $2 per share. The preferred shares have no other preferences other than upon liquidation, have no voting rights, and will be convertible into common stock on a one to one basis. The agreements contain a contingency clause that should the common share price drop below $2 per share between October to December, 2015, then the average of the daily high and low price over those subsequent 90 days will be taken, and additional preferred shares will be issued to equal that average 90 day price.

6. Common Stock

6. Common Stock	9 Months Ended
	Sep. 30, 2015
Notes
6. Common Stock	6. Common Stock On January 1, 2015, the Company’s board of directors authorized the issuance of 100,000 shares of its common stock to one of its officers. The value of the shares on the date of issuance was $690,000. As of September 30, 2015, the Company has recognized $517,500 in compensation expense related to this transaction with the remaining $172,500 being recorded as a prepaid. On January 1, 2015, the Company’s board of directors authorized the issuance of 10,000 shares of its common stock to each of its seven board of directors for each year of service. The Company issued 2,500 shares to each board member retroactive to the fourth quarter of 2014 in addition to 10,000 each for 2015 for a total of 12,500 shares each. The Company had recorded a liability in the amount of $120,750 related to the retroactive issuance in its December 31, 2014 financial statements. The Company recorded $362,250 in professional fees on its statement of operations for the nine months ended September 30, 2015 with an additional $120,750 being recorded as a prepaid on the Company’s balance sheet. On January 1, 2015, the Company’s board of directors authorized the issuance of 35,000 shares of its common stock to one of its officers for retroactive compensation in 2014. The value of the shares was determined to be $241,500 based on the trading price of the stock on the date of authorization. The Company had recorded a liability in the same amount in its balance sheet dated December 31, 2014. These shares were issued during the first quarter of 2015. On January 7, 2015, the Company’s board of directors authorized the issuance of 500,000 shares of its common stock to a consulting group for services to be provided during the year ended December 31, 2015. The value of the issuance was determined to be $3,500,000 based on the market value of the Company’s common stock on the date of issuance. The Company recorded $2,625,000 in consulting expense during the nine months ended September 30, 2015 related to this transaction with the remaining $875,000 being recorded as a prepaid as of September 30, 2015, which will be amortized over the remainder of the year. January 30, 2015, the Company’s board of directors authorized the issuance of 200,000 shares to two consultants for services to be provided during the year ended December 31, 2015. The value of the issuance was determined to be $1,640,000. The Company has recorded $1,230,000 in consulting expense during the nine months ended September 30, 2015 related to this transaction with the remaining $410,000 being recorded as prepaid as of September 30, 2015, which will be amortized over the remainder of the year. During the period ended September 30, 2015, the Company’s board of directors authorized the issuance of 80,000 shares to two consultants for services to be provided during the year ended December 31, 2015. The value of the issuance was determined to be $84,800. The Company has recorded $53,530 in consulting expense during the nine months ended September 30, 2015 related to this transaction with the remaining $31,270 being recorded as prepaid as of September 30, 2015, which will be amortized over the remainder of the year. During the period ended September 30, 2015, the Company’s board of directors authorized the issuance of 5,000 shares to the Company’s eighth (8th) board member for her services rendered April 1 through September 30, 2015. They were valued at $11,250.

7. Preferred Stock

7. Preferred Stock	9 Months Ended
	Sep. 30, 2015
Notes
7. Preferred Stock	7. Preferred Stock There are 5,000,000 preferred shares authorized with a par value of $.001. Of the preferred shares authorized, 5,000,000 have been designated Series A Convertible Preferred Stock. Through the period ended September 30, 2015, the Company has issued 1,928,585 shares of its Series A Convertible Preferred Stock for related party payables (see note 5). The rights and preferences of the Series A Convertible Preferred Stock are as follows: Dividends No Liquidation Preference Voting Rights Conversion No Preemptive Rights Effect of Stock Split

8. Hi Brands International Inc.

8. Hi Brands International Inc. - Centuria Foods Agreement	9 Months Ended
	Sep. 30, 2015
Notes
8. Hi Brands International Inc. - Centuria Foods Agreement	8. Hi Brands International Inc. – Centuria Foods Agreement On February 6, 2015, the Company formed Hi Brands International Inc., a Nevada Corporation and wholly owned subsidiary of Cannabis Sativa, Inc. On February 25, 2015, the Company through its wholly owned subsidiary Hi Brands International, Inc. (jointly referred to hereinafter as “Cannabis Sativa”), entered into a Purchase, Supply and Joint Venture Agreement (the “Agreement”), with Centuria Natural Foods, Inc. (“Centuria”) whereby Cannabis Sativa will market Centuria’s proprietary CBD (Cannabidiol) Rich Hemp Oil products (the “Products”). The initial term of the Agreement is one year which may be renewed for additional one year periods upon the mutual agreement of the parties. Within the first 90 days of the initial term of the Agreement, Cannabis Sativa shall order at least 5,000 units of Product. Thereafter, Cannabis Sativa shall order at least 5,000 units of Product per month with the additional requirement that Cannabis Sativa order a minimum of 55,000 units of Product during the first 12 months of the Agreement. Fifty percent of all gross revenue generated by the sale of the Products will be paid to Cannabis Sativa and fifty percent will be paid to Centuria. As of September 30, 2015, there has not been any activity in Hi Brands International Inc. other than the execution of the above agreement. The Company has not ordered any product under this agreement as of September 30, 2015.

9. Going Concern Considerations

9. Going Concern Considerations	9 Months Ended
	Sep. 30, 2015
Notes
9. Going Concern Considerations	9. Going Concern Considerations The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. The Company has incurred net losses since inception. As reported in the financial statements, the Company has an accumulated deficit of $52,469,812 which raises substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on its ability to raise adequate capital to fund operating losses until it is able to engage in profitable business operations. To the extent financing is not available, the Company may not be able to, or may be delayed in, developing its services and meeting its obligations. The Company will continue to evaluate its projected expenditures relative to its available cash and to evaluate additional means of financing in order to satisfy its working capital and other cash requirements. The accompanying financial statements do not reflect any adjustments that might result from the outcome of these uncertainties.

10. Legal Proceedings

10. Legal Proceedings	9 Months Ended
	Sep. 30, 2015
Notes
10. Legal Proceedings	10. Legal Proceedings On August 26, 2015 the Company filed a complaint in the District Court of Clark County, Nevada against 3 (three) individuals and Colonial Stock Transfer Company, Inc., a Utah Corporation, seeking declaratory relief for the cancelation of common shares of the Company issued in connection with a consulting agreement. The complaint alleges a breach of the consulting agreement by the defendants. In addition to seeking a cancellation of shares, the complaint seeks general, consequential and punitive damages and costs in unspecified amounts.

11. Subsequent Events

11. Subsequent Events	9 Months Ended
	Sep. 30, 2015
Notes
11. Subsequent Events	11. Subsequent Events Shareholders of Cannabis Sativa, Inc. received 4.32 shares of Kush for every share of ownership of common stock in the Company as a shareholder dividend on August 25, 2015. This will be completed on November 2, 2015. On October 6, 2015, the Company issued 2,500 shares of its common stock to a director of the Company. In accordance with the Kush spin off agreement, the Company is to issue 500,000 shares of its common shares to Kush. In return, for the 9% equity in Kush the Company shall receive 14,260,436 shares of Kush. On November 2, 2015, the Company announced that it will pay a special forward stock split dividend of 1.5 restricted common shares for each share held as of the record date of November 16, 2015. The holding period for these shares is 6 months from the issue date to shareholders of record. The Company has also submitted its application to be listed on NASDAQ.

1. Summary of Significant Acc17

1. Summary of Significant Accounting Policies and Use of Estimates (Policies)	9 Months Ended
	Sep. 30, 2015
Policies
Use of Estimates:	Use of Estimates: The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Accounts Receivable:	Accounts Receivable: We estimate credit loss reserves for accounts receivable on an individual receivable basis. A specific impairment allowance reserve is established based on expected future cash flows and the financial condition of the debtor. We charge off customer balances in part or in full when it is more likely than not that we will not collect that amount of the balance due. We consider any balance unpaid after the contract payment period to be past due. At September 30, 2015 the company has established an allowance for doubtful accounts of $3,697.
Inventory:	Inventory: The Company calculates inventory using the average cost method to value inventory. Inventory cost includes those costs directly attributable to the product before sale.
Fair Value of Financial Instruments:	Fair Value of Financial Instruments: The estimated fair values for financial instruments are determined at discrete points in time based on relevant market information. These estimates involve uncertainties and cannot be determined with precision. The carrying amounts of accounts payable, accrued liabilities, and notes payable approximate fair value given their short term nature or effective interest rates.
Cash and Cash Equivalents:	Cash and Cash Equivalents: For financial accounting purposes, cash and cash equivalents are considered to be all highly liquid investments purchased with an initial maturity of three (3) months or less.
Earnings Per Share:	Earnings per Share: Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of common shares outstanding for the period and contains no dilutive securities. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of an entity. As of September 30, 2015 and 2014, the Company has no outstanding potentially dilutive securities.
Revenue Recognition:	Revenue Recognition: The Company recognizes revenue from product sales or services rendered when the following four revenue recognition criteria are met: persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the selling price is fixed or determinable, and collectability is reasonably assured.
Intangible Assets:	Intangible Assets: Intangible assets are comprised of patents, trademarks, the Company’s “CBDS.com” website domain and intellectual property rights. The patent is being amortized using the straight-line method over its economic life, which is estimated to be twenty (20) years. The trademark, which is still in the application phase, is expected to have an indefinite useful life. The CBDS.com website is expected to have an indefinite useful life. The intellectual property rights are being amortized using the straight-line month over its economic life, which is estimated to be (20) years.
Income Taxes:	Income Taxes: The Company estimates the annual tax rate based on projected taxable income for the full year and records a quarterly income tax provision in accordance with the anticipated annual rate. As the year progresses, we refine the estimates of the year’s taxable income as new information becomes available, including year-to-date financial results. This continual estimation process can result in a change to the expected effective tax rate for the year. When this occurs, the Company adjusts the income tax provision during the quarter in which the change in estimate occurs so that the year-to-date provision reflects the expected annual tax rate. Significant judgment may be required in determining the Company’s effective tax rate and in evaluating our tax positions. The effective income tax rate of 0% for the periods ended September 30, 2015 and 2014 differed from the statutory rate, due primarily to net operating losses incurred by the Company in the respective periods. For the nine months ended September 30, 2015 a tax benefit of approximately $664,000 would have been generated. For the nine months ended September 30, 2014 a tax benefit of approximately $134,000 would have been generated. However, all benefits have been fully offset through an allowance account due to the uncertainty of the utilization of the net operating losses. As of September 30, 2015 the Company had net operating losses of approximately $17,925,000resulting in a deferred tax asset of approximately $664,000. As of September 30, 2014 the Company had net operating losses of approximately $336,000 resulting in a deferred tax asset of approximately $134,000. The Company has established a valuation allowance in the full amount of the deferred tax asset due to the uncertainty of the utilization of operating losses in future periods.
Pending Accounting Pronouncements:	Pending Accounting Pronouncements: There have been no recent accounting pronouncements issued which are expected to have a material effect on the Company’s financial statements.

1. Summary of Significant Acc18

1. Summary of Significant Accounting Policies and Use of Estimates (Tables)	9 Months Ended
	Sep. 30, 2015
Tables/Schedules
Pro Forma Condensed Combined Statement of Operations	The following unaudited proforma condensed combined statement of operations reflects the results of operations of CANNABIS SATIVA for the nine months ended September 30, 2014, the results of operations for WILD EARTH NATURALS for the nine months ended September 30, 2014, and the results of operations for KUSH for the nine months ended September 30, 2014 as if the Companies had been consolidated effective January 1, 2014. Cannabis Sativa Wild Earth Naturals Kush Proforma Revenue $- $2,786 $- $2,786 Cost of revenue - 2,018 - 2,018 Gross profit - 768 - 768 General and adminstrative expense 5,699 262,964 278,374 547,037 Other expense Realized loss from for sale securities - 377,440 377,440 Interest expense 6,908 11,823 - 18,731 Loss from continued operations (12,607) (274,019) (655,814) (942,440) Net loss $(12,607 $(274,019 $(655,814 $(942,440

3. Available-for-sale Securit19

3. Available-for-sale Securities (Tables)	9 Months Ended
	Sep. 30, 2015
Tables/Schedules
Schedule of Available-for-sale Securities	The following is a summary of the Company’s available-for-sale securities at September 30, 2015: Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value (Net Carrying Amount) Accumulated Other Comprehensive Income Equity Securities $- $4,876 $- $4,876 $4,876 Total Available-for-Sale Securities $- $4,876 $- $4,876 $4,876

4. Fair Value Measurements (Tab

4. Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Tables/Schedules
Schedule of Fair Value Measurements, Assets and Liabilities, Recurring Basis	As of September 30, 2015, assets and liabilities measured at fair value on a recurring basis were as follows: Total Level 1 Level 2 Level 3 Assets: Available-for-sale securities $4,876 $4,876 $- $- Total assets measured at fair value $4,876 $4,876 $- $- Liabilities: $- $- $- $- Total liabilities measured at fair value $- $- $- $-

1. Summary of Significant Acc21

1. Summary of Significant Accounting Policies and Use of Estimates: Pro Forma Condensed Combined Statement of Operations (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Revenue	$ 6,378	$ 1,114	$ 8,096	$ 2,786
Cost of revenue	13,172	387	14,575	2,018
Gross profit	(6,794)	727	(6,479)	768
General and administrative expense	1,762,707	171,132	5,413,153	336,293
Other Expenses
Realized loss from for sale securities		40,000		40,000
Interest expense	9,571	5,635	26,635	18,731
Net loss	$ (1,779,316)	$ (216,040)	$ (5,554,706)	(394,256)
Pro Forma
Revenue				2,786
Cost of revenue				2,018
Gross profit				768
General and administrative expense				547,037
Other Expenses
Realized loss from for sale securities				377,440
Interest expense				18,731
Loss from continued operations				(942,440)
Net loss				(942,440)
Wild Earth Naturals Inc
Revenue				2,786
Cost of revenue				2,018
Gross profit				768
General and administrative expense				262,964
Other Expenses
Realized loss from for sale securities				0
Interest expense				11,823
Loss from continued operations				(274,019)
Net loss				(274,019)
Kush
Revenue				0
Cost of revenue				0
Gross profit				0
General and administrative expense				278,374
Other Expenses
Realized loss from for sale securities				377,440
Interest expense				0
Loss from continued operations				(655,814)
Net loss				(655,814)
Cannabis Sativa
Revenue				0
Cost of revenue				0
Gross profit				0
General and administrative expense				5,699
Other Expenses
Interest expense				6,908
Loss from continued operations				(12,607)
Net loss				$ (12,607)

1. Summary of Significant Acc22

1. Summary of Significant Accounting Policies and Use of Estimates: Accounts Receivable (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Details
Allowance for doubtful accounts	$ 3,697

1. Summary of Significant Acc23

1. Summary of Significant Accounting Policies and Use of Estimates: Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Details
Dilutive securities outstanding	0	0

1. Summary of Significant Acc24

1. Summary of Significant Accounting Policies and Use of Estimates: Intangible Assets (Details)	9 Months Ended
	Sep. 30, 2015
Patents
Finite-Lived Intangible Asset, Useful Life	20 years
Intellectual Property
Finite-Lived Intangible Asset, Useful Life	20 years

1. Summary of Significant Acc25

1. Summary of Significant Accounting Policies and Use of Estimates: Income Taxes (Details) - USD ($)	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Details
Effective Income Tax Rate Reconciliation, Percent	0.00%
Federal Tax Benefit (Expense) at Statutory Rates	$ 664,000	$ 134,000
Operating Loss Carryforwards	17,925,000	336,000
Deferred Tax Assets	$ 664,000	$ 134,000

3. Available-for-sale Securit26

3. Available-for-sale Securities (Details) - USD ($)	Sep. 30, 2015	Sep. 29, 2015	Jan. 10, 2014
Share Price		$ 2
BioAdaptives, Inc.
Investment Owned, Balance, Shares			10,835
Share Price	$ 0.45
Investment Owned, Value	$ 4,876
Hemp, Inc.
Investment Owned, Balance, Shares			10,000,000

3. Available-for-sale Securit27

3. Available-for-sale Securities: Schedule of Available-for-sale Securities (Details)	9 Months Ended
	Sep. 30, 2015USD ($)
Details
Equity Securities, Amortized Cost	$ 0
Equity Securities, Gross Unrealized Gains	4,876
Equity Securities, Gross Unrealized Losses	0
Equity Securities, Fair Value (Net Carrying Amount)	4,876
Total Available-for-Sale Securities, Amortized Cost	0
Total Available-for-Sale Securities, Gross Unrealized Gains	4,876
Total Available-for-Sale Securities, Gross Unrealized Losses	0
Total Available-for-Sale Securities, Fair Value (Net Carrying Amount)	4,876
Total Available-for-Sale Securities, Accumulated Other Comprehensive Income	$ 4,876

4. Fair Value Measurements_ Sch

4. Fair Value Measurements: Schedule of Fair Value Measurements, Assets and Liabilities, Recurring Basis (Details)	Sep. 30, 2015USD ($)
Available-for-sale securities	$ 4,876
Total assets measured at fair value	4,876
Total liabilities measured at fair value	0
Fair Value, Inputs, Level 1
Available-for-sale securities	4,876
Total assets measured at fair value	4,876
Total liabilities measured at fair value	0
Fair Value, Inputs, Level 2
Available-for-sale securities	0
Total assets measured at fair value	0
Total liabilities measured at fair value	0
Fair Value, Inputs, Level 3
Available-for-sale securities	0
Total assets measured at fair value	0
Total liabilities measured at fair value	$ 0

5. Due To Related Parties (Deta

5. Due To Related Parties (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 29, 2015	Dec. 31, 2014	Jun. 30, 2014
Short-term advances from related parties			$ 58,500
Net advances	$ 0		$ 0
Debt Instrument, Interest Rate, Stated Percentage	5.00%		5.00%
Interest (expense)	$ 9,571	$ 5,635	$ 26,635	$ 18,731
Finite-Lived Intangible Assets, Accumulated Amortization	165,750		165,750
Non-Controlling Interest	894		894			$ 894
Finite-Lived Intangible Assets, Gross	$ 3,060,000		$ 3,060,000
Preferred Stock, par or stated value	$ 0.001		$ 0.001			$ 0.001
Share Price					$ 2
K-Pal
Fair Value of Assets Acquired			$ 8,938
Non-Controlling Interest	$ 894		894
Investor
Interest (expense)			25,742
Steven Kubby
Due to Related Parties, Current and Long-term							$ 3,060,000
Intellectual property gross sales price	$ 2,894,250		2,894,250
Liabilities Assumed			$ 2,890,499
Steven Kubby | Preferred Stock
Stock Issued to Subsidiary			1,500,000
Stock Issued During Period, Value, Purchase of Assets			$ 1,500
Steven Kubby | Additional Paid-in Capital
Stock Issued During Period, Value, Purchase of Assets			2,888,999
Three related parties
Debt Conversion, Original Debt, Amount			$ 857,170
Debt Conversion, Converted Instrument, Shares Issued			428,585
Three related parties | Preferred Stock with No voting rights
Debt Conversion, Description			a contingency clause that should the common share price drop below $2 per share between October to December, 2015, then the average of the daily high and low price over those subsequent 90 days will be taken, and additional preferred shares will be issued to equal that average 90 day price.

6. Common Stock (Details)

6. Common Stock (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Prepaids	$ 1,757,838	$ 625,000
Due to Related Parties - Short Term		2,472,086
Consultants
Shares issued for services, Value	3,500,000
Prepaids	875,000
Consulting expense	2,625,000
Consultants 2
Shares issued for services, Value	1,640,000
Prepaids	410,000
Consulting expense	1,230,000
Consultants 3
Shares issued for services, Value	84,800
Prepaids	31,270
Consulting expense	$ 53,530
Common Stock | Consultants
Shares issued for services, Shares	500,000
Common Stock | Consultants 2
Shares issued for services, Shares	200,000
Common Stock | Consultants 3
Shares issued for services, Shares	80,000
Officer 1
Shares issued for services, Value	$ 690,000
Allocated Share-based Compensation Expense	517,500
Prepaids	$ 172,500
Officer 1 | Common Stock
Shares issued for services, Shares	100,000
Director
Prepaids	$ 120,750
Due to Related Parties - Short Term		$ 120,750
Professional Fees	$ 362,250
Director | Common Stock
Shares issued for services, Shares	10,000	2,500
Officer 2
Shares issued for services, Value	$ 241,500
Officer 2 | Common Stock
Shares issued for services, Shares	35,000
Eighth board member
Shares issued for services, Value	$ 11,250
Eighth board member | Common Stock
Shares issued for services, Shares	5,000

7. Preferred Stock (Details)

7. Preferred Stock (Details) - $ / shares	9 Months Ended
	Sep. 30, 2015	Dec. 31, 2014
Preferred Stock, shares authorized	5,000,000	5,000,000
Preferred Stock, par or stated value	$ 0.001	$ 0.001
Preferred Stock, shares issued	1,928,585	0
Series A Preferred Stock
Preferred Stock, shares authorized	5,000,000
Preferred Stock, shares issued	1,928,585
Convertible Preferred Stock, Terms of Conversion	In connection with the spinoff of KUSH, a Nevada corporation, to the shareholders of the Company, all shares of the Series held by Steve Kubby shall be converted into 74,780,075 common shares of KUSH. Following this conversion, shares of the Series held by Mr. Kubby shall be returned to the treasury of the Company.

8. Hi Brands International In32

8. Hi Brands International Inc. - Centuria Foods Agreement (Details) - Centuria Natural Foods, Inc.	9 Months Ended
	Sep. 30, 2015
Minimum Product Order Size, per month	5,000
Minimum Product Order Size	55,000

9. Going Concern Consideratio33

9. Going Concern Considerations (Details) - USD ($)	Sep. 30, 2015	Dec. 31, 2014
Details
Accumulated Deficit	$ (52,469,812)	$ (46,915,104)

11. Subsequent Events (Details)

11. Subsequent Events (Details)	Oct. 16, 2015shares	Sep. 30, 2015shares	Dec. 31, 2014shares
Director | Common Stock
Shares issued for services, Shares		10,000	2,500
Subsequent Event | Common Stock
Stock Split Dividend Ratio		1.5
Subsequent Event | Kush
Stock Dividends Per Share		4.32
Stock Issued During Period, Shares, Spin off		500,000
Equity Method Investment, Ownership Percentage		9.00%
Shares of Subsidiary Issued		14,260,436
Subsequent Event | Director
Shares issued for services, Shares	2,500